Transpara™ for Mammography & DBT
Transpara™ is an FDA-cleared, CE-Class IIb AI system for screening and diagnostic breast imaging. It analyses 2-D mammograms and digital breast tomosynthesis (DBT) in seconds, highlights suspicious regions, and assigns an exam-level score (1–10) that helps radiologists prioritise high-risk patients and reduce reading time.
Transpara integrates directly into existing reading workstations, and is deployed in 30+ countries for both population screening and diagnostic workflows.
Key benefits
- Up to 7% increase in cancer detection and 40% reading-time reduction (multi-reader studies)
- Triages exams by risk score, so radiologists focus first on the highest-risk cases
- Works on FFDM and DBT from all major vendors (Hologic, GE, Siemens, Fuji, Philips)
- CE-MDR Class IIb and FDA 510(k) cleared for clinical use worldwide
Details
- Regulatory: FDA 510(k) K201486 • CE-MDR Class IIb
- Applications: Breast-cancer screening and diagnostic assessment
- Modality: 2-D mammography, DBT
- Body part: Breast
Clinical evidence
- Large Reader Study – Radiology 2021: 240 radiologists, +6% sensitivity and –30% recall when using Transpara.
- Dutch National Screening Trial (2023): Radiologist reading time cut by 40% with unchanged screening accuracy in 80,000 cases.
For the latest clinical evidence and updates, visit the company’s official website: https://www.screenpoint-medical.com/
Ask K2AI how Transpara™ can boost breast-cancer detection and cut reading time in your screening programme.
בניית אתרים JUNAMI